Explore the latest AMR resources

Discover our newest collection of resources covering topics such as antimicrobial resistance (AMR), antimicrobial stewardship, sepsis, and more. Browse our curated selection of blog posts, SmartNotes, and infographics to stay informed and up-to-date.


Comprehensive AST for MDR Gram negative infections, including sulbactam/durlobactam

Did you know we offer the only FDA-cleared automated AST assay for sulbactam/durlobactam susceptibility testing of Acinetobacter baumannii-calcoaceticus complex isolates? Choose from our IVD-labeled Sensititre Gram Negative MDRGN4F AST Plate or the research-use-only Sensititre Gram Negative MDRGNX4F* AST Plate, both providing comprehensive AST using second-line MDRO therapies with expanded dilution ranges for Gram-negative organisms to better detect emerging resistance.

 

*For research use only. Not for use in diagnostic procedures.


Speak to a specialist


Diagnostics: A crucial tool in the ongoing public health battle with antimicrobial resistance 

Despite a growing awareness of antimicrobial resistance (AMR) in recent years, it is one of the top ten threats to global public health and was associated with almost 5 million deaths in 2019. Its potential impact on the world’s economy is just as devastating, with the World Health Organization (WHO) predicting a $100 trillion impact by 2050 if no action is taken.

 

We simply cannot allow this to happen. But overcoming this monumental challenge will take a cross-sector effort in which we all, from clinicians to researchers, drug developers to diagnostics experts, play our part. 

Explore more:

Download our latest white paper to hear directly from the experts on the impact of definitive minimum inhibitory concentration (MIC) results on therapeutic treatment decisions and patient care


Antimicrobial stewardship needed to roll back the tide of COVID-driven AMR

We may have left the acute phase of the coronavirus pandemic behind us, but its legacy is still being felt in a number of ways – including the acceleration of antimicrobial resistance (AMR).

 

According the Centers for Disease Control and Prevention (CDC) figures, resistant hospital-onset infections and deaths both increased at least 15% in 2020, and the worrying trend continued into 2021.1 This was despite mortality from antimicrobial resistance decreasing by 18% overall and almost 30% in hospitals between 2012 and 2017.1 So what drove such significant change during the pandemic and post-pandemic period, and what does it tell us about the importance of antimicrobial stewardship (AMS)? 

Explore more:

How did the coronavirus pandemic contribute to antimicrobial resistance? Our SmartNote Post-viral syndrome - Tackling the COVID-driven increase in AMR starts in the laboratory looks at the data behind the facts. 


Infographic: Diagnostics in the antimicrobial stewardship jigsaw

Antimicrobial stewardship is a major weapon in the war on AMR – and effective diagnostics are a crucial part of the jigsaw puzzle. Because if we do not act, including using new and existing antibiotics as responsibly as possible, deaths from this “silent pandemic” could rise dramatically in the years ahead.¹


Balancing the dangers of sepsis and antimicrobial resistance

In recent years, awareness campaigns and policy decisions have contributed to a “better safe than sorry” approach to treating sepsis. However, such models mean patients may receive unnecessary antibiotics – a trend that can act as a contributing factor to the development of antimicrobial resistance (AMR). If we are to balance the twin dangers of sepsis and AMR, we need to consider how we utilize every weapon in our arsenal. 


¹WHO. (2019). New report calls for urgent action to avert antimicrobial resistance crisis. Available at: https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgentaction-to-avert-antimicrobial-resistance-crisis Last accessed: 31 July 2023

Availability of product in each country depends on local regulatory marketing authorization status.